2,165
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

, ORCID Icon, , , , , , , , & show all
Pages 722-724 | Received 15 Dec 2021, Accepted 15 Feb 2022, Published online: 09 Mar 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (1)